Using exosome analysis to diagnose upper gastrointestinal cancers
Plasma Extracellular Vesicle Quantitative Proteomic Analysis for Early Diagnosis of Upper Gastrointestinal Cancers
Beijing Friendship Hospital · NCT06278064
This study is trying to see if analyzing tiny particles in the blood can help doctors find upper gastrointestinal cancers earlier in patients compared to those with benign conditions or healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 562 (estimated) |
| Sex | All |
| Sponsor | Beijing Friendship Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Shijiazhuang, Hebei and 2 other locations) |
| Trial ID | NCT06278064 on ClinicalTrials.gov |
What this trial studies
This observational study collects and analyzes plasma samples from patients with upper gastrointestinal cancers, benign diseases, and healthy controls to identify protein biomarkers for early diagnosis. Utilizing advanced proteomics techniques, including Data-Independent Acquisition (DIA) and single-vesicle membrane protein detection, the study aims to quantify protein content within exosomes. A comprehensive database of tumor-specific exosome proteins will be constructed, and diagnostic models will be evaluated for their potential in early cancer detection. External validation of identified biomarkers will ensure their reliability across diverse patient populations.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with upper gastrointestinal cancers or benign diseases who have provided plasma samples prior to surgical treatment.
Not a fit: Patients who have received prior anti-tumor treatments or have other systemic tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of upper gastrointestinal cancers, improving patient outcomes.
How similar studies have performed: Similar studies utilizing exosome-based biomarkers have shown promise in cancer diagnostics, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of upper gastrointestinal cancers or benign upper gastrointestinal diseases through gastroscopy and pathological examination. * Collection of plasma samples prior to surgical treatment. * Availability of complete clinical data. Exclusion Criteria: * Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * Coexistence of other systemic tumors. * Absence of plasma sample collection before surgical treatment. * Incomplete clinical data. * Pregnancy status
Where this trial is running
Shijiazhuang, Hebei and 2 other locations
- The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (RECRUITING)
- Beijing Friendship Hospital, Capital Medical University — Beijing, China (RECRUITING)
- Cancer Hospital Chinese Academy of Medical Sciences — Beijing, China (RECRUITING)
Study contacts
- Principal investigator: Li Min, Ph.D. — Beijing Friendship Hospital
- Study coordinator: Li Min, Ph.D.
- Email: minli@ccmu.edu.cn
- Phone: +86 13552652141
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Gastric Cancer, Esophagus Cancer